Moleculin Biotech Stock Forum

$Moleculin Biotech (MBRX.US)$ Reuters· just
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of Stat3 Inhibitor in Combination With Radiation for the Treatment of Glioblastoma

$Moleculin Biotech (MBRX.US)$
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
– Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin
– Funding for study provided by NIH and BrainUp®
– Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune memory in glioblastoma animal models
HOUS...

$Moleculin Biotech (MBRX.US)$
Moleculin Announces Closing of up to $16.5 Million Public Offering

$Moleculin Biotech (MBRX.US)$
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech has completed its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine for treating AML (MB-106). The meeting focused on reviewing clinical data and planning the next steps, with official outcomes expected by Q3 2024. Interim results show that out of 22 enrolled subjects, 45% achieved a composite complete remiss...

$Moleculin Biotech (MBRX.US)$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study

$Moleculin Biotech (MBRX.US)$ Means the stock will go on a run soon which will then be stopped by adding shares. If you buy you might wanf try to sell before it reaches 30% gains.

$Moleculin Biotech (MBRX.US)$ Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

$Moleculin Biotech (MBRX.US)$ Reuters· 1 min ago
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

$Moleculin Biotech (MBRX.US)$
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...

$Moleculin Biotech (MBRX.US)$ Reuters· 1 min ago
Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data